KEY POINTS
- This retrospective MD Anderson Cancer Center cohort included 307 patients treated with external-beam radiotherapy followed by permanent low-dose-rate prostate brachytherapy boost between 1999 and 2024. 64.2% had high- or very-high-risk prostate cancer, approximately 35% had intermediate-risk disease, and 90.9% received androgen deprivation therapy.
- External-beam radiotherapy delivered a median 44 Gy in 22 fractions, using photons in 208 patients (67.8%) and protons in 99 (32.2%). The median brachytherapy prescription was 90 Gy, delivered predominantly using palladium-103 seeds (81%), with iodine-125 used in the remaining 19%.
- Treatment incorporated several modern planning approaches: MRI-assisted brachytherapy planning in 233 patients (75.9%), rectal spacers in 47 (15.3%), and immediate postimplant MRI-based verification. The median prostate D90 was 105 Gy, while median rectal V100 was approximately zero.
- At a median follow-up of 4.6 years, 22 patients (7.1%) experienced biochemical recurrence. Five-year biochemical recurrence-free survival was 95% overall, including 98% in intermediate-risk and 90% in high- or very-high-risk disease, while five-year overall survival was 92%.
- Among patients with biochemical failure, identified recurrence sites included three local recurrences, ten nodal recurrences, and nine distant metastatic events, with overlapping categories possible. Older age and higher Gleason score independently predicted worse overall survival; Gleason score ≥8 was associated with worse biochemical control in univariable analysis.
- Severe late toxicity was uncommon: grade ≥3 genitourinary toxicity occurred in 7 patients (2.3%), while the reported rate of grade ≥3 gastrointestinal toxicity was approximately 0.9%. GU events included urethral strictures requiring intervention and hematuria; one severe gastrointestinal complication involved a urethrorectal fistula requiring surgery.
- Late grade 2–4 GU toxicity was lower among patients treated from 2016 onward than before 2016 (12.0% vs 23.6%; OR 0.44, p=0.015). However, MRI-guided planning, treatment procedures, and supportive measures changed substantially over time, and this nonrandomized comparison cannot isolate which components contributed to the lower toxicity.
CLINICAL TAKEAWAY
EBRT combined with LDR brachytherapy boost produced favorable biochemical control and relatively low severe toxicity in this experienced institutional cohort, supporting its use in appropriately selected patients with unfavorable intermediate- or high-risk prostate cancer. These results should not be interpreted as demonstrating superiority over other dose-escalation strategies or proving that MRI guidance reduced toxicity, particularly given the long treatment era and limited comparative data.